National

Health Tech Deals

Olive is the buzzy startup whose purple “go save health care” busses dominate industry conferences. But its promises don't deliver, according to an Axios investigation that included interviews with 16 sources. 

Olive relies on rough estimations for its calculations, inflates its capabilities and, in many cases, generates only a fraction of the savings it pledges. 

Why it matters: Valued at $4 billion, Olive is the highest-profile startup in health care automation; a holy grail that promises to cut costs and direct more time toward patient care.

Go deeper: Read the full investigation in Axios Pro: Health Tech Deals

Buzzy health startup Olive fails to deliver on lofty promises

Olive is the buzzy startup whose purple busses promise to “go save health care."

Illustration of the Olive logo as a gas gauge on empty.

Health tech

Axios Investigates

Top Stories

Olive is the buzzy startup whose purple “go save health care” busses dominate industry conferences. But its promises don&#x27;t deliver, according to an Axios investigation that included interviews with 16 sources. <ul><li>Olive relies on rough estimations for its calculations, inflates its capabilities and, in many cases, generates only a fraction of the savings it pledges. </li></ul>Why it matters: Valued at $4 billion, Olive is the highest-profile startup in health care automation; a holy grail that promises to cut costs and direct more time toward patient care.Go deeper: <a class="gtmContentClick" data-vars-link-text="Read the full investigation" data-vars-click-url="https://www.axios.com/pro/health-tech-deals/2022/04/05/4-billion-health-tech-startup-olive-overpromises-and-underdelivers" data-vars-content-id="355c355f-3b9e-4cf3-9539-76624a2a7dd5" data-vars-headline="Buzzy health startup Olive fails to deliver on lofty promises" data-vars-event-category="story" data-vars-sub-category="story" data-vars-item="in_content_link" href="https://www.axios.com/pro/health-tech-deals/2022/04/05/4-billion-health-tech-startup-olive-overpromises-and-underdelivers" target="_self">Read the full investigation</a> in Axios Pro: Health Tech Deals

The U.S. faces a range of health care flashpoints — unaffordable drugs, opioids, vaping — as we debate whether to adopt universal care. For now, the Affordable Care Act is the law of the land, but Republicans want to issue it a final death blow.

Health

After a record economic expansion, the coronavirus pandemic sent the U.S. economy into a recession as unemployment soared to staggering heights. The country now faces urgent questions about how much stimulus is needed for reeling consumers and businesses, and what a recovery might look like.